登录

中风药物研发商RapidAI宣布AngioFlow™溶液获得FDA批准,用于血管造影室灌注成像

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

businesswire | 2024-05-06 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow™ by RapidAI solution.

加利福尼亚州圣马特奥(商业新闻短讯)--RapidAI是开发临床深度人工智能(AI)和技术工作流程解决方案以对抗威胁生命的神经血管、心脏和血管疾病的全球领导者,今天宣布,美国食品和药物管理局(FDA)已批准RapidAI solution对其AngioFlow™进行510(k)许可。

The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes..

该模块直接在介入套件中提供灌注成像分析,以提高临床信心,提高工作效率,并可能改善患者预后。。

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI.

RapidAI首席执行官卡里姆·卡蒂(KarimKarti)说:“我们很高兴扩大我们的中风AI成像组合,这是业界最广泛的组合,包括这个新模块。通过RapidAI的AngioFlow™,我们现在可以在整个患者路径上支持中风AI成像,从最初的非对比CT扫描一直到介入套件。”。

“Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”.

“已经在日本和欧洲注册和使用,我们相信这项技术将对美国中风患者的生活产生重大影响。”。

In acute stroke care where time is brain, timely intervention can be not only life-saving but can significantly reduce the risk of long-term disability. Used by care teams working in the interventional suite, AngioFlow™ by RapidAI draws on validated deep clinical AI to deliver clear, easy-to-interpret qualitative perfusion maps within minutes to help specialists assess ischemic change in brain regions with reduced cerebral blood flow..

在时间是大脑的急性中风护理中,及时干预不仅可以挽救生命,而且可以显着降低长期残疾的风险。RapidAI的AngioFlow™由介入套件的护理团队使用,它利用经过验证的深度临床AI,在几分钟内提供清晰,易于解释的定性灌注图,以帮助专家评估脑血流减少的大脑区域的缺血性变化。。

AngioFlow™ by RapidAI enhances operational efficiency and financial value by reducing redundant imaging and potentially saving time in patient care. Imaging at a referring facility allows physicians to evaluate the need for further scans in the interventional suite, accelerating clinical decisions and reducing unnecessary imaging.

RapidAI的AngioFlow™通过减少冗余成像并可能节省患者护理时间,提高了运营效率和财务价值。转诊机构的成像允许医生评估介入套件中进一步扫描的需求,加速临床决策并减少不必要的成像。

This is especially important in rural facilities and large hospital networks, where transfers may take hours to get from one facility to the next..

这在农村设施和大型医院网络中尤为重要,因为从一个设施到下一个设施的接送可能需要数小时。。

“AngioFlow™ by RapidAI will allow physicians to assess the need for additional imaging immediately in the interventional suite. By avoiding unnecessary scans, stroke patients can receive the timely care that can be the difference between being able to walk out of a hospital to their homes versus being discharged to a skilled nursing facility,” said Abhishek Singh, MD, DABPN, DUCNS at the Creighton University School of Medicine in Omaha, Nebraska..

“RapidAI的AngioFlow™将允许医生立即评估介入套件中额外成像的需求。通过避免不必要的扫描,中风患者可以得到及时的护理,这可能是能够走出医院回家与出院到熟练护理机构之间的区别,”内布拉斯加州奥马哈Creighton大学医学院DABPN医学博士Abhishek Singh说。。

To learn more about how RapidAI is transforming stroke care, please visit: https://www.rapidai.com/

要了解RapidAI如何改变中风护理的更多信息,请访问:https://www.rapidai.com/

About RapidAI

RapidAI

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 14 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible.

RapidAI是使用人工智能对抗威胁生命的血管和神经血管疾病的全球领导者。RapidAI领导着临床决策和患者工作流程的下一次演变,它使医生能够更快地做出决策,以获得更好的患者结果。根据100多个国家2200多家医院1400万次扫描获得的情报,Rapid®平台改变了护理协调,为护理团队提供了前所未有的患者可见度。

RapidAI – where AI meets patient care..

RapidAI–人工智能与患者护理相结合的地方。。

推荐阅读

中风药物研发商RapidAI卒中人工智能系统AngioFlow获FDA批准

伍斯特郡急性医院为中风患者实施人工智能软件

Digital Health 2024-05-01 15:39

NICE推荐在NHS中使用两种由人工智能驱动的软件工具e-Stroke和RapidAI

pharmaphorum 2024-01-23 16:22

businesswire

6563篇

最近内容 查看更多

研究性Seladelpar在原发性胆汁性胆管炎的肝病进展和瘙痒减少方面表现出显著改善

17 小时前

Mirum Pharmaceuticals的LIVMARLI数据在ESPGHAN年会上展示

18 小时前

Oak Hill Bio和Chiesi Group宣布第一名患者参与恢复的2b期临床研究,评估OHB-607预防支气管肺发育不良,支气管肺发育异常是早产儿慢性肺病的最常见原因

2 天前

相关公司查看更多

RapidAI

中风和脑血管成像技术及产品研发商

立即沟通

产业链接查看更多

所属赛道

医学影像
近30天,融资2起
数字疗法-神经系统疾病
动脉橙产业智库梳理了:神经系统类疾病数字治疗相关公司、关联事件100+;产业图谱、产品获批、TOP公司作战地图等分析维度持续更新。
数字疗法-中风
动脉橙产业智库梳理了:中风数字疗法相关公司、关联事件100+;近10年投融资总额超过4亿美元;产业图谱、政策内参、TOP公司作战地图等分析维度,并将持续更新。